Real world experience in 150 genotype 1 HCV patients with triple therapy: severe adverse events and high rates of virological failure in cirrhotic patients with portal hypertensio…
J Petersen, K Voelker, K Olah, K Matschenz, H Wolski, C Czaja-Harder, F Kuhlendahl, A Plettenberg, T Lorenzen, S Unger, A Stoehr, P Buggisch · Zeitschrift für Gastroenterologie · 2013 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background and aim: Newly approved HCV GT1 triple regimens are complex and associated with additional toxicities. Besides RCT results, only limited data are available for BOC und TVR under real life conditions, especially for difficult to treat patients with non-response and advanced liver disease. Methods: Data from 150 patients who initiated triple therapy apart from clinical studies or Early-Access-Programs with BOC (n = 73) or TVR (n = 77) at the IFI Institute were obtained from medical record review and analysed on an intention to treat basis. Hemoglobin level < 9 g/dl or a > 4.5 g/dl decrease from baseline…
